Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene's need for speed behind $500m antibody alliance with Sutro

This article was originally published in Scrip

Executive Summary

Sutro Biopharma hopes to announce one or two more collaborations with Big Pharma or large biotech companies within the next 12 months that will be similar to the San Francisco-based company's $500 million-plus deal with Celgene to design and develop novel antibody-drug conjugates (ADCs) and bi-specific antibodies for two undisclosed targets, and to manufacture an antibody from Celgene's early-stage pipeline.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts